FDA 483 - Degasa S.A. De C.V. - May 27, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Degasa S.A. De C.V. in Jiutepec, Mexico, from May 23-27, 2022, revealed numerous deficiencies in their drug manufacturing operations. The firm was cited for issues including inadequate raw material sampling, incomplete laboratory records, lack of data integrity controls, and an insufficient stability program. Additionally, observations noted problems with facility construction, equipment design, contamination prevention, and an inadequate number of qualified personnel.
ID · 634bf82c-0610-40fc-b7f8-34e16086a76c